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Abstract: - Safinamide (SAF) is an anti-Parkinson’s disease (PD) drug that has selective monoamine oxidase type-B (MAO-B) 
inhibition activity. In 2017, SAF was approved by the U.S. Food and Drug Administration (FDA) as safinamide mesylate (SAF-MS, 
marketed as Xadago). In this study, salts of safinamide with hydrochloric acid (HCl), hydrobromic acid (HBr), and maleicacid (MA) 
were obtained and characterized using differential scanning calorimetry (DSC). Differential scanning calorimetry methods are 
usually employed to assess the thermodynamic stability of solid forms the proposed method provides accurate and precise quality 
control tool for routine analysis of Safinamide mesylate in bulk and in tablet dosage form 2013 Trade Science Inc. – INDIA. 
Key Words: —Parkinson’s disease (PD), Safinamide (SAF), Differential scanning calorimetry (DSC), Hydrochloric acid (HCl),  acid (HBr), 
and Maleicacid (MA). 
I. INTRODUCTION 
Safinamidemesylate (SAF) is an orally available derivative 
from chemical class of a amino amides, with multiple 
mechanisms of action involving inhibition of MAO-B and 
Dopamine reuptake used in the treatment of epilepsy and 
Parkinson.s disease. Chemically, Safinamidemesylate is, (S)-
(+)-2-[4-(3-fluorobenzyloxybenzylamino) propanamide] 
methanesulfonate(1:1 salt).The chemical structure is shown in 
Figure 1.[1, 2]. 
Previous studies on the solubility of SAF and related salts have 
been conducted using the excessive powder dissolution 
method. 
 
Fig.1. Chemical structure of Safinamide Mesylate. 
Literature survey reveals a validated chiral liquid 
chromatographic method for the enantiomeric separation of 
safinamidemesylate[3] and bioassay of safinamide in biological 
fluids of humans and various animal species [4]. 
Except this, so far no analytical method was available 
forestimation of SAF as indicated by detail literature survey. 
The therapeutic effectiveness and less methods available for its 
estimation encourage us to undertake this work, so that 
quantitative estimation of SAF can be done and hence can be 
used for routine analysis of bulk and formulation as well. 
The antiparkinson mechanism of safinamide is through 
reversible inhibition of selective MAO-B, as a mesylate salt, 
thus reducing the degradation of dopamine. 
It inhibits glutamate release and dopamine reuptake in the brain. 
Safinamide also blocks sodium and calcium channels, although 
the clinical significance of this to PD is unknown. 
II. EXPERIMENTAL AND STABILITY STUDIES 
Safinamide (SAF) was gifted from Alembic Pharma, Munbai. 
(M S). Differential scanning calorimetry(DSC) was performed 
on a Mettler-Toledo machine at a rate of heating of 10 0C/min 
within the range of 25–250oC under nitrogen flow at a rate of 
20 mL/min. 
The stability studies of SAF and its salts was performed under 
different humidity environments at 25oC. The different relative 
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humidity treatments were 75% (sodium chloride in saturated 
state), 85% (potassium chloride in saturated state), and 97% 
(potassium sulfate in saturated state). The samples were placed 
in an incubator after 14 days and assessed using PXRD data. 
III. RESULTS AND DISCUSSION 
A. Thermal Analysis: 
Differential scanning method is usually employed to assess the 
thermodynamic stability of solid forms. Herein, the DSC and 
TG curves of SAF and all salts are shown in Figure 7 and Figure 
S1. The DSC curves of SAF, SAF-HCl, SAF-HBr, and SAF-
MA showed an end of thermic peak at 1360C, 2310C, 2280C, 
and 1820C, respectively, with the temperature attributed to 
Crystals 2020, 10, 989 7 of 11the melting point of the solid 
forms. The DSC curve of SAF-MA-H2Oexhibited abroad peak 
in the range of 50–1100C, which may be attributed to the 
release of water in the crystal cell. Another end of thermic peak 
at 182 0C was observed, which was assigned to the melting 
point of SAF-MA-H2O. The TGcurves of SAF, SAF-HCl, 
SAF-HBr, and SAF-MA began to decompose with the 
formation of volatile compound(s) at 200 0C, 224 0C, 2220C, 
and 177 0C, respectively. The TG curves of SAF-MA-
H2Oshowed a weight loss of 4.38% at the range of 50–110 0C, 
which was attributed to water loss (calculated4.13%). SAF-
MA-H2O began to decompose at 177 0C, which meant that the 
melting observed was a melting/degradation due to the fact that 
the baseline was not reached after the phase transition, 




The formulations of safinamide were subjected to accelerated 
stability studies after filling into hard gelatin capsules shells. 
The evaluated method is very simple. Therefore, the DSC 
method was proved to be suitable for the safinamide 
determination in tablets. 
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